Eli Lilly & Company (LLY) is a global leader in human pharmaceuticals, trading under the symbol “LLY” on the NYSE. The latest analysis suggests that the stock could rise to between $1144.39 and $1196.17, as it remains above the low set on December 10, 2025, completing wave ((3)). From a weekly viewpoint, the stock shows a bullish trend, moving toward an all-time high. Key points in this trend include: a low of $64.18 in November 2016 marking wave (II), a high of $937.96 in August 2024 for wave (III), and a low of $623.78 in August 2025 for wave (IV). Wave (III) demonstrated strong momentum, while wave (IV) experienced a double correction. Right now, the stock is in the I of (V) rally stage, with wave ((3)) forecasted to rise within the $1144.39 to $1196.17 range. Since the low on December 10, 2025, the rally has consist of seven upward movements, with two more highs expected before the next correction. Smart buying opportunities could occur during pullbacks of three, seven, or eleven swings in wave ((4)), or later in wave II of (V) against the low of August 8, 2025. Keep in mind that markets are unpredictable, so it’s essential to do your own research before making any trades. Overall, Eli Lilly appears to be in a strong upward movement, targeting $1144.40 to $1196.17 soon. This trend holds as long as the stock stays above the December 10, 2025 low. This momentum is part of a larger rally that began in August 2025. The technical outlook is further supported by solid fundamentals. In Q3 2025, the company reported that sales of its weight-loss drugs exceeded expectations by over 15%, a trend we anticipate will continue. Additionally, positive early results for its Alzheimer’s treatment, Donanemab, boost this optimistic forecast. For options traders, it may be wise to buy call options on any small dips in the coming days or weeks. Another approach could be selling cash-secured puts at lower strike prices to earn premiums while taking advantage of the expected upward movement. Currently, low market volatility, with the VIX recently below 14, makes buying options less expensive. We should also brace for a brief pullback, as the current rally segment is nearing completion before a short correction. This potential dip might provide the ideal entry point, especially if the price stays above the crucial support level from December 10, 2025. A drop below that level would require a complete reassessment of this bullish perspective.

here to set up a live account on VT Markets now